Agonistic monoclonal antibodies targeting tumor necrosis factor receptors, such as OX40, GITR, and CD137 expressed on several immune cells, provoke the extension of CD8+ T-cell survival, increasing tumor-specific T-cell responses, the upregulation of NK cells, and the regulation of regulatory T-cells [34,35,36]. Here, CD8A is linked to neoplasm.